Answering key data governance questions raised by COVID-19
The coronavirus crisis is raising key governance questions regarding the handling of health data. Frameworks can help societies develop the data approach that works for their populations.
Dr. Seiichiro Yamamoto joined the National Cancer Center as staff scientist in 1996, after a Ph.D was conferred from the School of Health Sciences, Faculty of Medicine of The University of Tokyo. He has supported cancer clinical research projects as a biostatistician while also leading epidemiological research projects throughout his career. He has authored or co-authored over 110 original articles in peer-reviewed journals including New England Journal of Medicine, Lancet, Journal of National Cancer Institute, Lancet Oncology, Journal of Clinical Oncology. He was visiting researcher at the Division of Cancer Therapy and Diagnosis of National Cancer Institute in the USA, and also served at the Office of Medical Innovation, Cabinet Secretariat, Government of Japan. He is an advisor of Japan Clinical Oncology Group Data Center, a councilor of several academic associations including the Japanese Society of Medical Oncology and Japanese Epidemiology Association, and an editorial board member of Japanese Journal of Clinical Oncology and Breast Cancer. He has been focusing on for these ten years the research for precision medicine for individual cancer prevention using health behavioral approach and also a principal investigator of the world largest breast cancer patient survivorship cohort. He is also a principal investigator of development and management of e-learning website for clinical research methodology “ICRweb (Introduction to Clinical Research, http:/icrweb.jp/)”. ICRweb provides more than 200 contents for 90,000 users and is a de-fact standard training tools for medical doctors involved in clinical research in Japan.
Based on the knowledge and experiences so far, he is now focusing on the healthcare data policy in the era of the fourth industrial revolution.